Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 AffimedViking TherapeuticsBeyondSpringNeoleukin TherapeuticsSpectrum Pharmaceuticals
SymbolNASDAQ:AFMDNASDAQ:VKTXNASDAQ:BYSINASDAQ:NLTXNASDAQ:SPPI
Price Information
Current Price$8.98$5.67$9.50$12.22$2.92
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.61.61.21.41.5
Analysis Score3.53.63.33.53.4
Community Score2.93.52.61.72.8
Dividend Score0.00.00.00.00.0
Ownership Score0.80.80.01.70.8
Earnings & Valuation Score0.60.00.00.00.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$13.80$16.44$32.67$22.67$9.75
% Upside from Price Target53.67% upside190.03% upside243.86% upside85.49% upside233.90% upside
Trade Information
Market Cap$849.70 million$440.69 million$373.02 million$510.88 million$444.27 million
Beta2.812.020.61.092.51
Average Volume3,258,0631,360,142267,565243,7402,585,659
Sales & Book Value
Annual Revenue$23.96 millionN/AN/A$25 million$109.33 million
Price / Sales33.10N/AN/A20.694.11
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$0.57 per share$3.83 per share$1.12 per share$2.91 per share$1.69 per share
Price / Book15.75N/AN/A4.201.73
Profitability
Net Income$-36,250,000.00$-25,780,000.00$-38,080,000.00$-69,440,000.00$-112,690,000.00
EPS($0.56)($0.36)($1.55)($0.75)($1.14)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-172.01%N/AN/AN/AN/A
Return on Equity (ROE)-99.24%-13.57%-221.67%-24.06%-98.90%
Return on Assets (ROA)-37.40%-13.14%-139.97%-21.92%-69.77%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/A0.09%N/A0.05%
Current Ratio2.24%27.08%2.78%20.88%3.48%
Quick Ratio2.24%27.09%2.78%20.88%3.48%
Ownership Information
Institutional Ownership Percentage52.33%54.13%7.10%65.70%63.56%
Insider Ownership PercentageN/A3.70%N/A7.10%5.04%
Miscellaneous
Employees137186165175
Shares Outstanding88.33 million77.18 million39.14 million42.33 million153.73 million
Next Earnings Date6/22/2021 (Estimated)4/29/2021 (Estimated)6/10/2021 (Estimated)5/5/2021 (Estimated)5/6/2021 (Estimated)
OptionableOptionableOptionableNot OptionableOptionableOptionable
SourceHeadline
 Brokerages Expect Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Will Announce Earnings of -$0.33 Per Share Brokerages Expect Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Will Announce Earnings of -$0.33 Per Share
americanbankingnews.com - April 17 at 3:12 AM
Double dose of Spectrum Pharmas poziotinib improves tolerability in NSCLC patientsDouble dose of Spectrum Pharma's poziotinib improves tolerability in NSCLC patients
seekingalpha.com - April 14 at 12:34 AM
Check This Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Analysis Before You InvestCheck This Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Analysis Before You Invest
stocksregister.com - April 12 at 8:35 AM
Spectrum Pharmaceuticals (SPPI) Buy Rating Reiterated at B. RileySpectrum Pharmaceuticals' (SPPI) Buy Rating Reiterated at B. Riley
americanbankingnews.com - April 12 at 8:30 AM
Spectrum Pharmaceuticals Presentations at the Upcoming AACR Virtual Meeting 2021 to Include Updated Poziotinib Twice Daily Dosing DataSpectrum Pharmaceuticals Presentations at the Upcoming AACR Virtual Meeting 2021 to Include Updated Poziotinib Twice Daily Dosing Data
finance.yahoo.com - April 5 at 9:38 AM
Cantor Fitzgerald Research Analysts Lift Earnings Estimates for Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)Cantor Fitzgerald Research Analysts Lift Earnings Estimates for Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)
americanbankingnews.com - April 2 at 9:14 AM
Q1 2021 Earnings Estimate for Spectrum Pharmaceuticals, Inc. Issued By Jefferies Financial Group (NASDAQ:SPPI)Q1 2021 Earnings Estimate for Spectrum Pharmaceuticals, Inc. Issued By Jefferies Financial Group (NASDAQ:SPPI)
americanbankingnews.com - April 2 at 8:18 AM
Keith M. Mcgahan Sells 3,939 Shares of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) StockKeith M. Mcgahan Sells 3,939 Shares of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Stock
americanbankingnews.com - April 1 at 10:16 PM
Spectrum Pharmaceuticals, Inc. to Post FY2025 Earnings of $1.53 Per Share, Jefferies Financial Group Forecasts (NASDAQ:SPPI)Spectrum Pharmaceuticals, Inc. to Post FY2025 Earnings of $1.53 Per Share, Jefferies Financial Group Forecasts (NASDAQ:SPPI)
americanbankingnews.com - April 1 at 9:02 AM
Spectrum Pharmaceuticals (NASDAQ:SPPI) Announces Quarterly  Earnings Results, Meets EstimatesSpectrum Pharmaceuticals (NASDAQ:SPPI) Announces Quarterly Earnings Results, Meets Estimates
americanbankingnews.com - March 31 at 7:28 AM
BRIEF-Spectrum Pharmaceuticals Reports Fourth Quarter 2020 And Full Year 2020 Financial ResultsBRIEF-Spectrum Pharmaceuticals Reports Fourth Quarter 2020 And Full Year 2020 Financial Results
msn.com - March 30 at 8:05 PM
Spectrum Pharma: Q4 Earnings SnapshotSpectrum Pharma: Q4 Earnings Snapshot
ourmidland.com - March 30 at 8:05 PM
Spectrum Pharmaceuticals Reports Fourth Quarter 2020 and Full Year 2020 Financial Results and Pipeline UpdateSpectrum Pharmaceuticals Reports Fourth Quarter 2020 and Full Year 2020 Financial Results and Pipeline Update
finance.yahoo.com - March 30 at 8:04 PM
-$0.31 EPS Expected for Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) This Quarter-$0.31 EPS Expected for Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) This Quarter
americanbankingnews.com - March 29 at 2:26 PM
Spectrum Pharmaceuticals (SPPI) Scheduled to Post Quarterly Earnings on TuesdaySpectrum Pharmaceuticals (SPPI) Scheduled to Post Quarterly Earnings on Tuesday
americanbankingnews.com - March 29 at 8:34 AM
Spectrum Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate UpdateSpectrum Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update
finance.yahoo.com - March 26 at 8:16 PM
Spectrum Pharmaceuticals Provides Update on ROLONTIS® (eflapegrastim) Pre-Approval InspectionSpectrum Pharmaceuticals Provides Update on ROLONTIS® (eflapegrastim) Pre-Approval Inspection
finance.yahoo.com - March 16 at 10:27 AM
Spectrums (SPPI) NSCLC Drug Gets FDAs Fast Track DesignationSpectrum's (SPPI) NSCLC Drug Gets FDA's Fast Track Designation
finance.yahoo.com - March 12 at 5:31 PM
SPPI Stock Price Increases Over 20% Pre-Market: Why It HappenedSPPI Stock Price Increases Over 20% Pre-Market: Why It Happened
pulse2.com - March 11 at 12:49 PM
FDA Grants Fast Track Designation to Spectrum Pharmaceuticals’ PoziotinibFDA Grants Fast Track Designation to Spectrum Pharmaceuticals’ Poziotinib
finance.yahoo.com - March 11 at 7:49 AM
How Much Of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Do Institutions Own?How Much Of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Do Institutions Own?
finance.yahoo.com - March 3 at 1:16 PM
Spectrum Pharmaceuticals Presents Twice Daily Dosing Data for Poziotinib at the ESMO TAT Virtual Congress 2021Spectrum Pharmaceuticals Presents Twice Daily Dosing Data for Poziotinib at the ESMO TAT Virtual Congress 2021
finance.yahoo.com - March 2 at 2:42 PM
Spectrum Pharmaceuticals Announces Poster Presentation at Upcoming Miami Breast Cancer ConferenceSpectrum Pharmaceuticals Announces Poster Presentation at Upcoming Miami Breast Cancer Conference
finance.yahoo.com - February 26 at 7:41 AM
Spectrum Pharmaceuticals Announces Two Presentations at Upcoming ESMO TAT Virtual Congress 2021Spectrum Pharmaceuticals Announces Two Presentations at Upcoming ESMO TAT Virtual Congress 2021
finance.yahoo.com - February 23 at 9:57 AM
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI): It Is A Stock Worth Considering TodaySpectrum Pharmaceuticals, Inc. (NASDAQ:SPPI): It Is A Stock Worth Considering Today
marketingsentinel.com - February 5 at 7:38 PM
DateCompanyBrokerageAction
4/18/2021AffimedSVB LeerinkReiterated Rating
4/12/2021AffimedBMO Capital MarketsBoost Price Target
3/30/2021AffimedCredit Suisse GroupInitiated Coverage
3/30/2021AffimedWells Fargo & CompanyBoost Price Target
8/9/2020AffimedLaidlawReiterated Rating
10/11/2018AffimedSunTrust BanksLower Price Target
8/28/2018AffimedJefferies Financial GroupUpgrade
1/22/2021Viking TherapeuticsStifel NicolausReiterated Rating
10/29/2020Viking TherapeuticsRaymond JamesBoost Price Target
9/11/2020Viking TherapeuticsWilliam BlairReiterated Rating
9/10/2020Viking TherapeuticsB. RileyReiterated Rating
9/1/2020Viking TherapeuticsBTIG ResearchBoost Price Target
8/31/2020Viking TherapeuticsChardan CapitalBoost Price Target
8/28/2020Viking TherapeuticsHC WainwrightBoost Price Target
7/29/2020Viking TherapeuticsOppenheimerReiterated Rating
5/2/2020Viking TherapeuticsMaxim GroupInitiated Coverage
1/11/2021BeyondSpringBank of AmericaInitiated Coverage
12/28/2020BeyondSpringEvercore ISIInitiated Coverage
1/10/2020BeyondSpringNomura SecuritiesInitiated Coverage
4/11/2021Neoleukin TherapeuticsMizuhoReiterated Rating
9/22/2020Neoleukin TherapeuticsRobert W. BairdInitiated Coverage
8/12/2020Neoleukin TherapeuticsPiper SandlerBoost Price Target
6/25/2020Neoleukin TherapeuticsCanaccord GenuityReiterated Rating
2/18/2020Neoleukin TherapeuticsGuggenheimInitiated Coverage
9/17/2020Spectrum PharmaceuticalsJMP SecuritiesInitiated Coverage
7/28/2020Spectrum PharmaceuticalsCantor FitzgeraldBoost Price Target
(Data available from 4/20/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.